{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=11",
    "query": {
      "intervention": "Single intravenous doses of placebo",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 677,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T21:53:32.916Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04117607",
      "title": "Safety and Pharmacokinetics of Rezafungin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fungal Infection"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Rezafungin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 14,
      "start_date": "2019-12-04",
      "completion_date": "2020-05-11",
      "has_results": true,
      "last_update_posted_date": "2021-07-16",
      "last_synced_at": "2026-10-14T21:53:32.916Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04117607"
    },
    {
      "nct_id": "NCT01438853",
      "title": "Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sepsis",
        "Acute Lung Injury",
        "Acute Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "TNX-832",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Altor BioScience",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2004-12",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2025-01-06",
      "last_synced_at": "2026-10-14T21:53:32.916Z",
      "location_count": 6,
      "location_summary": "Miami, Florida • Boston, Massachusetts • St Louis, Missouri + 3 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01438853"
    },
    {
      "nct_id": "NCT02036645",
      "title": "SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mild-Moderate Alzheimer's Disease",
        "Healthy Elderly"
      ],
      "interventions": [
        {
          "name": "MEDI1814 for IV injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI1814 for Subcutaneous Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IV Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for Subcutaneous Injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 77,
      "start_date": "2014-02-04",
      "completion_date": "2016-09-15",
      "has_results": true,
      "last_update_posted_date": "2019-06-03",
      "last_synced_at": "2026-10-14T21:53:32.916Z",
      "location_count": 10,
      "location_summary": "Glendale, California • Long Beach, California • Panorama City, California + 7 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Panorama City",
          "state": "California"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02036645"
    },
    {
      "nct_id": "NCT04419467",
      "title": "Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Kidney Disease (DKD)"
      ],
      "interventions": [
        {
          "name": "CSL346",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2020-09-14",
      "completion_date": "2022-10-24",
      "has_results": true,
      "last_update_posted_date": "2023-12-06",
      "last_synced_at": "2026-10-14T21:53:32.916Z",
      "location_count": 22,
      "location_summary": "Covina, California • Fresno, California • Lomita, California + 15 more",
      "locations": [
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Lomita",
          "state": "California"
        },
        {
          "city": "Lynwood",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04419467"
    },
    {
      "nct_id": "NCT07445971",
      "title": "A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID -19",
        "COVID-19 (Prevention)"
      ],
      "interventions": [
        {
          "name": "MDX2301",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModeX Therapeutics, An OPKO Health Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 80,
      "start_date": "2026-03-24",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-14T21:53:32.916Z",
      "location_count": 2,
      "location_summary": "Las Vegas, Nevada • Austin, Texas",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07445971"
    },
    {
      "nct_id": "NCT05875948",
      "title": "Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatorenal Syndrome",
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "R2R01",
          "type": "DRUG"
        },
        {
          "name": "Terlipressin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "River 2 Renal Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2023-06-30",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2023-10-03",
      "last_synced_at": "2026-10-14T21:53:32.916Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05875948"
    },
    {
      "nct_id": "NCT00877032",
      "title": "Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Age-Related Maculopathy",
        "Age-Related Maculopathies",
        "Eye Diseases",
        "Retinal Degeneration",
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "RN6G",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2009-04",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2015-03-31",
      "last_synced_at": "2026-10-14T21:53:32.916Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Glendale, California • Inglewood, California + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00877032"
    },
    {
      "nct_id": "NCT02920021",
      "title": "Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "Etokimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AnaptysBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-01-26",
      "completion_date": "2018-03-30",
      "has_results": true,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-10-14T21:53:32.916Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California • Seattle, Washington",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02920021"
    },
    {
      "nct_id": "NCT06406348",
      "title": "A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "ALIA-1758",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 53,
      "start_date": "2024-05-09",
      "completion_date": "2025-04-22",
      "has_results": false,
      "last_update_posted_date": "2025-07-17",
      "last_synced_at": "2026-10-14T21:53:32.916Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06406348"
    },
    {
      "nct_id": "NCT04988152",
      "title": "A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "sotrovimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to Biologic",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Vir Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2021-07-06",
      "completion_date": "2021-12-07",
      "has_results": true,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-10-14T21:53:32.916Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • Glendale, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04988152"
    }
  ]
}